STAAR Surgical Company (STAA) - 10-K Summary
Business Context and Reporting Period
Company: STAAR Surgical Company
Filing Type: Form 10-K (Annual Report)
Period Ended: January 1, 2010
Business Overview: STAAR designs, develops, manufactures, and sells implantable lenses for the eye, specifically Intraocular Lenses (IOLs) for cataract surgery and Implantable Collamer Lenses (ICLs) for refractive surgery. The company operates as a single segment with significant international exposure (79% of sales in fiscal 2009).
Key Subsequent Event: On March 2, 2010, the company completed the divestiture of its German distribution subsidiary, Domilens GmbH, for approximately $12.5 million in net cash proceeds.
Key Financial Metrics (Fiscal Year 2009)
| Metric | 2009 | 2008 | Change |
|---|---|---|---|
| Net Sales | $75.3 million | $74.9 million | +0.6% |
| Gross Profit | $41.9 million | $40.1 million | +4.5% |
| Gross Margin | 55.6% | 53.6% | +200 bps |
| Operating Loss | $(3.7) million | $(20.4) million | Improved |
| Net Loss | $(6.2) million | $(23.2) million | Improved |
| Cash from Operations | $1.4 million | $(8.2) million | Positive for first time in 6 years |
| Working Capital | $13.5 million | $10.8 million | + |
| Total Assets | $58.7 million | $52.6 million | + |
Debt & Liquidity: As of January 1, 2010, the company held $6.3 million in cash and cash equivalents. Significant debt obligations include a $5.0 million note payable to Broadwood Partners (due Dec 2010) and a $2.2 million line of credit in Japan. The company has an accumulated deficit of $132.1 million.
Material Changes vs. Prior Period
- Profitability Improvement: Net loss decreased significantly from $23.2 million in 2008 to $6.2 million in 2009, driven by cost reduction initiatives and a reversal of accrued litigation costs.
- Cash Flow Turnaround: The company generated $1.4 million in positive cash flow from operations in 2009, reversing six consecutive years of negative operating cash flow.
- Product Mix Shift: Sales of ICLs (refractive) increased 15% globally, while sales of "Other Surgical Products" (lower margin) decreased 15% as the company deemphasized this category.
- Legal Resolution: Two major lawsuits (Parallax and Moody) resulting in judgments totaling over $11 million were settled in March 2010 for $4.0 million, significantly reducing future legal expenses and uncertainty.
- Divestiture: The sale of Domilens (which accounted for 32% of 2009 sales) was completed in Q1 2010 to raise working capital and improve gross margins by removing low-margin third-party distribution sales.
Guidance, Outlook, and Risks
2010 Operational Goals:
- Achieve double-digit growth in core ICL and IOL sales.
- Improve gross profit margins to the mid-60% level.
- Progress toward profitability with a goal of achieving net income for the full year.
- Continue generation of positive cash flow.
Management Commentary: Management expects the divestiture of Domilens to significantly improve gross margins. The company anticipates lower legal expenses in 2010 due to the settlement of pending litigation. Growth in the U.S. refractive market remains challenged by the economic recession, though the company believes its ICL product is gaining market share.
Key Risks & Contingencies:
- Liquidity: Limited working capital and history of losses create a risk of needing additional financing. The company must repay the $5 million Broadwood note in December 2010 and faces a potential $6.8 million redemption of Series A Preferred Stock in December 2010.
- Regulatory: FDA approval for the Toric ICL (TICL) in the U.S. remains pending; delays could impact growth in the refractive market.
- Market Conditions: Continued global recession may suppress demand for elective refractive surgery.
- Concentration: 79% of sales are international, exposing the company to currency fluctuations and foreign regulatory risks.
Investor Verification Checklist
- Cash Runway: Verify if the $12.5 million from the Domilens sale plus operating cash flow is sufficient to cover the $5 million Broadwood note and potential $6.8 million preferred stock redemption due in late 2010.
- Domilens Impact: Confirm the actual impact of the Domilens divestiture on Q1 2010 revenue and gross margin, as this subsidiary represented 32% of prior year sales.
- TICL Approval Status: Monitor FDA communications regarding the Toric ICL application, as this is a critical growth driver for the U.S. market.
- Legal Settlement Finality: Ensure the $4 million settlement payment for the Parallax and Moody cases is fully executed and that no further litigation costs are accrued.
- U.S. IOL Sales Trend: Track whether the introduction of new aspheric IOLs (nanoFLEX) successfully reverses the multi-year decline in U.S. IOL sales volume.